Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 478–479 (2006)Cite this article

boxed-textThe OASIS-6 Trial Group (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295: 1519–1530

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Antman EM et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44: E1–E211

  2. Yusuf S et al.; CREATE Trial Group Investigators (2005) Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 293: 427–436

    Article  CAS  Google Scholar 

  3. Yusuf S et al. (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354: 1464–1476

    Article  CAS  Google Scholar 

  4. Buller HR et al. (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349: 1695–1702

    Article  CAS  Google Scholar 

  5. Buller HR et al. (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140: 867–873

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Assistant Professor of Medicine, McMaster University, Hamilton, ON, Canada

    Lori-Ann Linkins & Jeffrey I Weitz

  2. Professor of Medicine and Biochemistry, McMaster University, Hamilton, ON, Canada

    Jeffrey I Weitz

Authors
  1. Lori-Ann Linkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey I Weitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey I Weitz.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linkins, LA., Weitz, J. OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. Nat Rev Cardiol 3, 478–479 (2006). https://doi.org/10.1038/ncpcardio0635

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0635

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing